Hybrid 11C-MET PET/MRI Combined With “Machine Learning” in Glioma Diagnosis According to the Revised Glioma WHO Classification 2016
Authors:
- Sied KebirSKSied Kebir
- Manuel WeberMWManuel Weber
- Lazaros LazaridisLLLazaros Lazaridis
- Teresa SchmidtTSTeresa Schmidt
- Kathy KeyvaniKKKathy Keyvani
- Daniela PierscianekDPDaniela Pierscianek
- Ulrich SureUSUlrich Sure
- 1 March 2019
- journal article
- research article
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 44 (3) , 214-220
Abstract
Purpose: With the advent of the revised WHO classification from 2016, molecular features, including isocitrate dehydrogenase (IDH) mutation have become important in glioma subtyping. This pilot trial analyzed the potential for 11C-methionine (MET) PET/MRI in classifying glioma according to the revised WHO classification using a machine learning model. Methods: Patients with newly diagnosed WHO grade II–IV glioma underwent preoperative MET-PET/MRI imaging. Patients were retrospectively divided into four groups: IDH wild-type glioblastoma (GBM), IDH wild-type grade II/III glioma (GII/III-IDHwt), IDH mutant grade II/III glioma with codeletion of 1p19q (GII/III-IDHmut1p19qcod) or without 1p19q-codeletion (GII/III-IDHmut1p19qnc). Within each group, the maximum tumor-to-brain-ratio (TBRmax) of MET-uptake was calculated. To gain generalizable implications from our data, we made use of a machine learning algorithm based on a development and validation subcohort. A support vector machine model was fit to the development subcohort and evaluated on the validation subcohort. Receiver operating characteristic (ROC) analysis served as metric to assess model performance. Results: Of a total of 259 patients, 39 patients met the inclusion criteria. TBRmax was highest in the GBM cohort (TBRmax 3.83 ± 1.30) and significantly higher (P = 0.004) compared to GII/III-IDHmut1p19qnc group, where TBRmax was lowest (TBRmax 2.05 ± 0.94). ROC analysis showed poor AUC for glioma subtyping (AUC 0.62) and high AUC of 0.79 for predicting IDH status. In the GII/III-IDHmut1p19qcod group, TBR values were slightly higher than in the IDHmut1p19qnc group. Conclusions: MET-PET/MRI imaging in pre-operatively classifying glioma entities appears useful for the assessment of IDH status. However, a larger trial is needed prior to translation into the clinical routine.Keywords
This publication has 17 references indexed in Scilit:
- The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summaryActa Neuropathologica, 2016
- Performance of18F-FET versus18F-FDG-PET for the diagnosis and grading of brain tumors: systematic review and meta-analysisNeuro-Oncology, 2015
- Machine learning: Trends, perspectives, and prospectsScience, 2015
- Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entitiesActa Neuropathologica, 2015
- Template for Reporting Results of Biomarker Testing of Specimens From Patients With Tumors of the Central Nervous SystemArchives of Pathology & Laboratory Medicine, 2015
- 11C-Methionine Uptake Correlates with Combined 1p and 19q Loss of Heterozygosity in Oligodendroglial TumorsAmerican Journal of Neuroradiology, 2012
- Hot spots in dynamic18FET-PET delineate malignant tumor parts within suspected WHO grade II gliomasNeuro-Oncology, 2011
- Diagnostic Accuracy of 11C-Methionine PET for Differentiation of Recurrent Brain Tumors from Radiation Necrosis After RadiotherapyJournal of Nuclear Medicine, 2008
- FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour gradingEuropean Journal of Nuclear Medicine and Molecular Imaging, 2007
- Cerebral blood volume, genotype and chemosensitivity in oligodendroglial tumoursNeuroradiology, 2006